SPROUT User Publications

The First Small-Molecule Inhibitors of Members of the Ribonuclease E Family

Louise Kime, Helen A. Vincent, Deena M. A. Gendoo, Stefanie S. Jourdan, Colin W. G. Fishwick, Anastasia J. Callaghan, Kenneth J. McDowall

Scientific Reports
2015, 5, pp 8028-8028

ARTICLE

In Silico Design and Biological Evaluation of a Dual Specificity Kinase Inhibitor Targeting Cell Cycle Progression and Angiogenesis

Antony M. Latham, Jayakanth Kankanala, Gareth W. Fearnley, Matthew C. Gage, Mark T. Kearney, Shervanthi Homer-Vanniasinkam, Stephen B. Wheatcroft, Colin W. G. Fishwick, Sreenivasan Ponnambalam

PLoS ONE
2014, 9

ARTICLE

Molecular mechanism of ligand recognition by membrane transport protein, Mhp1

Katie J. Simmons, Scott M. Jackson, Florian Brueckner, Simon G. Patching, Oliver Beckstein, Ekaterina Ivanova, Tian Geng, Simone Weyand, David Drew, Joseph Lanigan, David J. Sharples, Mark S.P. Sansom, So Iwata, Colin W.G. Fishwick, A. Peter Johnson, Alexander D. Cameron, Peter J.F. Henderson

The EMBO Journal
2014, 33, pp 1831-1844

ARTICLE

Applications of structure-based design to antibacterial drug discovery

R. Cain, S. Narramore, M. McPhillie, K. Simmons, C.W.G. Fishwick

Bioorg. Chem.
2014, 55, pp 69-74

ABSTRACT

Assay Platform for Clinically Relevant Metallo-ß-lactamases

Sander S. van Berkel, Jurgen Brem, Anna M. Rydzik, Ramya Salimraj, Ricky Cain, Anil Verma, Raymond J. Owens, Colin W. G. Fishwick, James Spencer, Christopher J. Schofield

J. Med. Chem.
2013, 56(17), pp 6945-6953

ARTICLE

Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design

N.Y. Mok, J. Chadwick, K.A. Kellett, E. Casas-Arce, N.M. Hooper, A.P. Johnson, C.W. Fishwick

J. Med. Chem.
2013, 56 (5), pp 1843-1852

MANUSCRIPT

A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis

J. Kankanala, A.M. Latham, A.P. Johnson, S. Homer-Vanniasinkam, C.W.G. Fishwick, S. Ponnambala

British Journal of Pharmacology
2012, 166 (2), pp 737-748

ARTICLE

Structure-based discovery of antibacterial drugs

Katie J. Simmons, Ian Chopra, Colin W. G. Fishwick

Nature Reviews Microbiology
2010, 8 (7), pp 501-510

ABSTRACT

Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases

Matthew Davies, Timo Heikkila, Glenn A. McConkey, Colin W. G. Fishwick, Mark R. Parsons, A. Peter Johnson

J. Med. Chem.
2009, 52 (9), pp 2683-2693

ABSTRACT

Design and synthesis of new hydroxyethylamines as inhibitors of D-alanyl-D-lactate ligase (VanA) and D-alanyl-D-alanine ligase (DdlB)

Matej Sova, Gasper Cadez, Samo Turk, Vita Majce, Slovenko Polanc, Sarah Batson, Adrian J. Lloyd, David I. Roper, Colin W. G. Fishwick, Stanislav Gobec

Bioorg. Med. Chem. Lett.
2009, 19 (5), pp 1376-1379

ABSTRACT

Synthesis of de novo designed small-molecule inhibitors of bacterial RNA polymerase

Anil K. Agarwal, A. Peter Johnson, Colin W. G. Fishwick

Tetrahedron
2008, 64 (43), pp 10049-10054

ABSTRACT

Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core

Jon J. Hangeland, Daniel L. Cheney, Todd J. Friends, Stephen Swartz, Paul C. Levesque, Adam J. Rich, Lucy Sun, Terry R. Bridal, Leonard P. Adam, Diane E. Normandin, Natesan Murugesan, William R. Ewing

Bioorg. Med. Chem. Lett.
2008, 18 (2), pp 474-478

ABSTRACT

Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase

Timo Heikkila, Christopher Ramsey, Matthew Davies, Christophe Galtier, Andrew M. W. Stead, A. Peter Johnson, Colin W. G. Fishwick, Andrew N. Boa, Glenn A. McConkey

J. Med. Chem.
2007, 50 (2), pp 186-191

ABSTRACT

The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase

Timo Heikkila, Srinath Thirumalairajan, Matthew Davies, Mark R. Parsons, A. Glenn McConkey, Colin W. G. Fishwick, A. Peter Johnson

Bioorg. Med. Chem. Lett.
2006, 16 (1), pp 88-92

ABSTRACT

A novel de novo designed inhibitor of D-ala-D-ala ligase from E.coli.

Gilbert E. Besong, Julieanne M. Bostock, Will Stubbings, Ian Chopra, David I. Roper, Adrian J. Lloyd, Colin W. G. Fishwick, A. Peter Johnson

Angew. Chem. Int. Ed. Engl.
2005, 44 (39), pp 6403 - 6406

ABSTRACT

The first de novo-designed antagonists of the human NK2 receptor

Mohammed A. Ali, Nirmala Bhogal, John B. C. Findlay, Colin W. G. Fishwick

J. Med. Chem.
2005, 48 (18), pp 5655-5658

ABSTRACT

Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors

Qi Han, Celia Dominguez, Pieter F. W. Stouten, Jeongsook M. Park, Daniel E. Duffy, Robert A. Galemmo, Jr., Karen A. Rossi, Richard S. Alexander, Angela M. Smallwood, Pancras C. Wong, Matthew M. Wright, Joseph M. Luettgen, Robert M. Knabb, Ruth R. Wexler

J. Med. Chem.
2000, 43 (23), pp 4398-4415

ABSTRACT

Molecular modeling in the discovery of drug leads

George W. A. Milne, Shaomeng Wang, and Marc C. Nicklaus

J. Chem. Inf. Comp. Sci.
1996, 36 (4), pp 726-730

ABSTRACT